Back to Feed
ClinicalTrials.gov|Clinical Trial
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Beijing GoBroad Hospital
Abstract
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE). Phase: PHASE1, PHASE2 Status: RECRUITING Conditions: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN) Interventions: CD19 CAR-T cells
Keywords
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)